<DOC>
	<DOCNO>NCT02380573</DOCNO>
	<brief_summary>A double-blind , placebo-controlled study aim investigate effect 2-week 12-week administration USP methylene blue ( MB ) cerebral blood flow , functional connectivity , memory attention cognitive ability use fMRI behavioral measure healthy aging , mild cognitive impairment ( MCI ) mild Alzheimer 's disease ( AD ) subject .</brief_summary>
	<brief_title>Cognitive Functional Connectivity Effects Methylene Blue Healthy Aging , Mild Cognitive Impairment Alzheimer 's Disease</brief_title>
	<detailed_description>Healthy age age human subject mild cognitive impairment mild Alzheimer 's disease TARCC cohort South Texas study use double-blind , placebo-controlled design . After informed consent familiarity task MRI environment , subject enter MRI scanner perform follow 6 task . fMRI behavioral data collect simultaneously inside scanner . Delayed match-to-sample task : The subject view pattern second prompt recall memorized pattern use response system ( approx . 10 min ) . Face-name task : The subject show block stimuli novel familiar face pair name . In late run , subject ask whether correct name match correct face . ( approx . 10 min ) . Psychomotor vigilance task : The subject receive visual cue alert press button fast possible . ( approx . 10 min ) . Cerebral Blood Flow Resting State fMRI : Subject scan eye close told think particular topic , last 10 minute . fMRI data acquisition : fMRI neuropsychological battery measurement make intervention . These measurement repeat 2 week 12 week . fMRI image change regional brain activity associate task . The MRI pulse sequence include diffusion tensor imaging , standard non-invasive anatomical quantitative MRI coregistration blood-oxygen-level dependent ( BOLD ) fMRI . CO2 challenge : Cerebral blood flow measurement obtain subject rest scanner administration medical-grade 5 % CO2 air 3-5 minute . This repeated week 2 12 . Data analysis : Standard fMRI analysis analyze use establish fMRI software . Statistical parametric analysis perform generate activation map . fMRI data correct multiple comparison use false discovery rate ( q &lt; 0.05 ) threshold cluster value conservatively control type I error . Behavioral data analyze paired t-test ANOVA calculation use group comparison p &lt; 0.05 ( Bonferroni correction ) consider statistically significant . Expected result : The investigator predict , compare placebo , MB : ) improve work memory retention delay match-to-sample task memory performance enhance fMRI response prefrontal cortex parietal lobe , ii ) improve episodic memory determine fMRI activation hippocampus , medial temporal lobe prefrontal cortex iii ) reduce reaction time psychomotor vigilance test enhance fMRI response within cortical sustain attention network iv ) improve CBF v ) improve fMRI connectivity default mode visuospatial memory networks/subnetworks . The fMRI behavioral performance effect memory great MCI mild AD group healthy age group . The effect great MCI AD group control group . Power analysis : Sample size calculate use fMRI power tool base pilot data current study power 80 % , alpha = 0.05 , False Discovery Rate &lt; 0.05 , detect statistical difference MB placebo23 . The investigator estimate need 20-25 subject per arm group ( complete study ) thus recruit 200-240 subject account potential failed study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Inclusion Criteria subject : 1 . 4589 year old 2 . All gender 3 . All minority 4 . English , Spanish , multilingual speaker 5 . Postmenopausal surgically sterile female . 6 . Inclusion MCI group : participant meet criterion amnestic nonamnestic MCI currently use Texas Alzheimer 's Research Care Consortium ( TARCC ) consensus diagnosis 7 . Inclusion AD group : Alzheimer 's Earlystage , sporadictype 1 . Pregnancy breastfeed 2 . Contraindication MRI ( Claustrophobia magnetic metal implant ) 3 . Glucose6phosphate deficiency , methemoglobinemia 4 . Allergy MB 5 . Colorblindness 6 . Craniotomy , craniectomy endovascular neurosurgery 7 . A current diagnosis stroke , transient ischemic attack ( TIA ) , primary neurodegenerative disorder , cause neuropsychologic disturbance secondary dementia ( MCI AD exclude subject ) 8 . A serious intercurrent illness likely cause death within next 5 year , terminal cancer 9 . Alcohol and/or drug abuse 10 . Any detection unknown disease process ( eg . new tumor ) study 's neuroimaging discretion investigator 11 . A systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥105 mmHg 12 . Severe difficulty inability perform one 6 Katz Activities Daily Living 13 . Patients unlikely comply trial visit schedule trial medication , 14 . On psychiatric serotonergic antidepressant medication psychotropic medication within last 5 week 15 . Diagnosis epilepsy , traumatic brain injury loss consciousness , psychosis , panic attack , 16 . Chronic kidney disease , cirrhosis , liver renal transplant 17 . Known hypersensitivity thiazide diuretic phenothiazines 18 . Any condition , opinion investigator , would put participant risk warrant exclusion study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>methylene blue</keyword>
	<keyword>fMRI</keyword>
</DOC>